What does total daily dose (TDD) refer to in insulin therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is TDD (Total Daily Dose) in Insulin Therapy?

TDD stands for Total Daily Dose and refers to the complete amount of insulin (measured in units) that a person with diabetes receives over a 24-hour period, including all basal (background) insulin and bolus (mealtime/correctional) insulin combined.

Core Definition and Components

TDD encompasses the sum of:

  • Basal insulin: The background insulin delivered continuously (typically 40-50% of TDD in most patients) 1, 2
  • Bolus/prandial insulin: Mealtime insulin doses (typically 50-60% of TDD)
  • Correctional insulin: Additional doses given to correct hyperglycemia

The TDD is typically expressed as units per kilogram per day (units/kg/day) to standardize dosing across different body weights 1.

Clinical Application by Setting

Hospitalized Patients (Non-ICU)

For insulin-naïve patients with type 2 diabetes:

  • Standard starting dose: 0.3-0.5 units/kg/day 1
  • Mild hyperglycemia (glucose <200 mg/dL): Consider 0.1-0.2 units/kg/day 2
  • Moderate hyperglycemia (glucose 201-300 mg/dL): Start 0.2-0.3 units/kg/day 2
  • Severe hyperglycemia (glucose >300 mg/dL): Start 0.3 units/kg/day 2

High-risk populations require dose reduction 1:

  • Elderly patients: 0.20-0.25 units/kg/day
  • Impaired kidney function: 0.20-0.25 units/kg/day
  • Poor caloric intake: 0.20-0.25 units/kg/day
  • Patients already on insulin with poor oral intake: Reduce home TDD by 20-25%

Outpatient Insulin Initiation

For type 2 diabetes requiring insulin 3:

  • A1C <8%: Start basal insulin at 0.1-0.2 units/kg TDD
  • A1C ≥8%: Start basal insulin at 0.2-0.3 units/kg TDD
  • Distribute as 50% basal and 50% prandial when using basal-bolus regimens

ICU to Floor Transition

When transitioning from IV insulin infusion to subcutaneous insulin 1:

  • Calculate TDD as ~80% of IV insulin used in the preceding 12-24 hours
  • Split into basal and bolus components
  • Patients requiring <1-2 units/hour IV may not need scheduled subcutaneous insulin

Distribution of TDD

Standard basal-bolus split 1, 2:

  • 50% as basal insulin (given once or twice daily)
  • 50% as prandial insulin (divided among meals)

Alternative distribution for glucocorticoid-induced hyperglycemia 4:

  • 40% basal, 60% prandial
  • Or 30% basal, 70% prandial for high-dose steroids

Titration Principles

Fixed regimen approach 3:

  • Increase TDD by 2 units every 2-5 days based on fasting glucose

Adjustable regimen approach 3:

  • Fasting glucose >180 mg/dL: Add 20% of TDD
  • Fasting glucose 140-180 mg/dL: Add 10% of TDD
  • Fasting glucose 110-139 mg/dL: Add 1 unit

For hypoglycemia 3:

  • Glucose <70 mg/dL: Reduce TDD by 10-20%
  • Glucose <40 mg/dL: Reduce TDD by 20-40%

Common Pitfalls

Avoid these errors:

  • Using sliding scale insulin alone as the sole method of glucose control (strongly discouraged) 1
  • Premixed insulin formulations (70/30) in hospitals—associated with significantly higher hypoglycemia rates 1
  • Discontinuing insulin in patients already on therapy at home—creates severe hyperglycemia risk 1
  • Failing to reduce TDD in elderly, renally impaired, or poorly eating patients—increases hypoglycemia risk 1

Real-World Variations

TDD requirements vary significantly:

  • Type 1 diabetes: Mean 0.9 units/kg/day in children (range 0.6-1.3) 5
  • Newly diagnosed type 1 diabetes: Increases from ~27 units/day at diagnosis to ~66 units/day at 48 months 6
  • Type 2 diabetes on CSII vs MDI: CSII requires lower TDD than multiple daily injections 7
  • Day-to-day variability: Coefficient of variation ~23% even with closed-loop systems 6

Key factors affecting TDD 7:

  • Body mass index and waist circumference
  • Fasting plasma glucose and HbA1c levels
  • Insulin delivery method (pump vs injections)

References

Guideline

american association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2022

Guideline

management of diabetes and hyperglycaemia in the hospital.

The Lancet Diabetes and Endocrinology, 2021

Guideline

american association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2023

Guideline

glucocorticoid-induced hyperglycemia including dexamethasone-associated hyperglycemia in covid-19 infection: a systematic review.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.